Mergers & Acquisitions Sun Pharma Acquires Ranbaxy Laboratories

Editor: Dominik Stephan

Sun Pharmaceutical Industries Ltd plans to acquire Ranbaxy Laboratories Ltd for US$ 4 billion. The combination of Sun Pharma and Ranbaxy creates the fifth-largest specialty generics company in the world and the largest pharmaceutical company in India.

Related Companies

Sun Pharma Acquires Ranbaxy Laboratories
Sun Pharma Acquires Ranbaxy Laboratories
(Picture: PROCESS)

Mumbai/India -The combined entity will have operations in 65 countries, 47 manufacturing facilities across five continents, and a significant platform of specialty and generic products marketed globally, including 629 ANDAs.

Talking about the acquisition, Managing Director, Sun Pharma, Dilip Shanghvi said, “Ranbaxy has a significant presence in the Indian pharma market and in the US where it offers a broad portfolio of ANDAs and first-to-file opportunities. In high-growth emerging markets, it provides a strong platform, which is highly complementary to Sun Pharma’s strengths. We see tremendous growth opportunities and are excited with the prospects to create lasting value for both our shareholders through a successful combination of our franchises.”